Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effect of Vitamin D Supplementation During Caloric Restriction on Intestinal Calcium Absorption
This study is currently recruiting participants.
Study NCT00472654   Information provided by National Institute on Aging (NIA)
First Received: May 10, 2007   Last Updated: September 11, 2008   History of Changes
This Tabular View shows the required WHO registration data elements as marked by

May 10, 2007
September 11, 2008
March 2007
Changes in Calcium absorption [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00472654 on ClinicalTrials.gov Archive Site
Changes in serum and urine bone markers, hormones, proteins and genes [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
Same as current
 
The Effect of Vitamin D Supplementation During Caloric Restriction on Intestinal Calcium Absorption
Nutritional Regulation of Bone - Aim 3

The purpose of this study is to learn how the amount of vitamin D supplementation influences intestinal fractional calcium absorption (a measure of the amount of calcium absorbed).

The extent of change in the amount of calcium that is absorbed with an increase in vitamin D supplementation is not known. This information is important for determining appropriate vitamin D requirements for optimal calcium absorption. During caloric restriction in postmenopausal women, we found that serum parathyroid hormone (PTH) explains 22% of the variance for the reduced calcium absorption (equivalent to 400 IU of Vitamin D per day). It is possible that higher dietary Vitamin D will increase serum 25-hydroxy-Vitamin D (25(OH)D) levels, offset serum PTH and thereby prevent a reduction in calcium absorption. This study seeks to determine if a high Vitamin D intake (a supplement of 1200 IU per day) can increase true fractional calcium absorption (TFCA) in postmenopausal women on a standard high-carbohydrate weight loss diet compared to weight maintenance, with the hypothesis that a high Vitamin D intake will raise serum 25(OH)D and offset the decline in TFCA during caloric restriction (vs. an increase in weight-stable women), and serum PTH will no longer be a major factor explaining changes in TFCA.

Participants will be recruited for both weight loss and weight maintenance, and all will be randomly assigned to take either 1200 IU per day vitamin D supplement or matching placebo. All weight loss participants will attend 5-6 weekly counseling sessions (about 50 minutes per session). All participants will be asked to take a daily vitamin/mineral supplement and, depending on their usual food intake, they may be asked to take a calcium tablet to meet the recommended intake throughout the study period. To measure calcium absorption before and after the 6 weeks of weight loss, participants will go to the study site after an overnight fast where an IV will be placed and the participant will receive an infusion of a stable calcium isotope and consume a 4 oz beverage that also contains a stable isotope of calcium. Blood will be drawn, and then the participant will be asked to collect all urine for the next 24 hours. Body composition (fat, muscle mass, and bone mineral density) will be measured by a dual-energy x-ray absorptiometry (DXA) machine and peripheral quantitative computer tomography (pQCT).

Participants will only be recruited in the winter and spring of each year.

 
Interventional
Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
  • Weight Loss
  • Bone Density
  • Behavioral: Weight Loss
  • Dietary Supplement: Vitamin D 1200 IU
  • Behavioral: Weight Maintenance
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
84
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Postmenopausal women who are more than 2 years since last menses
  • Obese or overweight
  • Must live in the geographic vicinity of Rutgers University

Exclusion Criteria:

  • Currently on any medication known to influence calcium or bone metabolism, including HRT, or with evidence of diseases known to influence calcium metabolism (i.e. metabolic bone disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, or renal disease, significant cardiac disease [i.e., heart attack or stroke in the past 6 months., abnormal EKG], active malignancy or cancer therapy within the past year)
  • History of kidney stones
  • Weight gain or weight loss (5% of body wt) within 3 months prior to recruitment
  • Participation in other investigational studies during the 12-month study period
  • Travel for longer than 2 consecutive weeks during the study period
  • Usually have a very high or low intake of calcium (more than 1500 or less than 500 mg per day)
Female
50 Years to 70 Years
Yes
 
United States
 
 
NCT00472654
Sue Shapses, PhD, RD, Rutgers University
RO1-AG12161
National Institute on Aging (NIA)
Rutgers University
Principal Investigator: Sue Shapses, PhD, RD Rutgers University, Nutritional Sciences
National Institute on Aging (NIA)
September 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.